Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angel Guzman-Perez

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 20, 2012
Discovery of new piperidine amide triazolobenzodiazepinones as intestinal-selective CCK1 receptor agonistsKimberly O Cameron, Elena E Beretta, Yue Chen, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 2013
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motifKevin J Filipski, Angel Guzman-Perez, Jianwei Bian, et al.
Chemical Research in Toxicology|May 29, 2010
Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosisAmit S Kalgutkar, David A Griffith, Tim Ryder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2025
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer ModelsRaymond A Pagliarini, Jack A Henderson, Benjamin C Milgram, et al.
Journal of Medicinal Chemistry|July 22, 2016
Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 InhibitorsErin F DiMauro, Stephen Altmann, Loren M Berry, et al.
Journal of Medicinal Chemistry|December 14, 2011
Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylaseKevin D Freeman-Cook, Paul Amor, Scott Bader, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2012
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitusJeffrey A Pfefferkorn, Meihua Tu, Kevin J Filipski, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 2007
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosisLeonard Buckbinder, David T Crawford, Hong Qi, et al.
Bioorganic & Medicinal Chemistry Letters|November 17, 2012
Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitorsSamit K Bhattacharya, Gary E Aspnes, Scott W Bagley, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formationDaniel P Walker, F Christopher Bi, Amit S Kalgutkar, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|March 20, 2012
Discovery of new piperidine amide triazolobenzodiazepinones as intestinal-selective CCK1 receptor agonistsKimberly O Cameron, Elena E Beretta, Yue Chen, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 2013
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motifKevin J Filipski, Angel Guzman-Perez, Jianwei Bian, et al.
Chemical Research in Toxicology|May 29, 2010
Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosisAmit S Kalgutkar, David A Griffith, Tim Ryder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2025
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer ModelsRaymond A Pagliarini, Jack A Henderson, Benjamin C Milgram, et al.
Journal of Medicinal Chemistry|July 22, 2016
Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 InhibitorsErin F DiMauro, Stephen Altmann, Loren M Berry, et al.
Journal of Medicinal Chemistry|December 14, 2011
Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylaseKevin D Freeman-Cook, Paul Amor, Scott Bader, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2012
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitusJeffrey A Pfefferkorn, Meihua Tu, Kevin J Filipski, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 2007
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosisLeonard Buckbinder, David T Crawford, Hong Qi, et al.
Bioorganic & Medicinal Chemistry Letters|November 17, 2012
Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitorsSamit K Bhattacharya, Gary E Aspnes, Scott W Bagley, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formationDaniel P Walker, F Christopher Bi, Amit S Kalgutkar, et al.
Pageof 5